27473951|t|Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
27473951|a|Disease incidence differs between males and females for some infectious or inflammatory diseases. Sex-differences in immune responses to some vaccines have also been observed, mostly to viral vaccines in adults. Little evidence is available on whether sex-differences occur in response to immunisation in infancy even though this is the age group in which most vaccines are administered. Factors other than sex, such as timing or coadministration of other vaccines, can also influence the immune response to vaccination. Individual participant data meta-analysis of randomised controlled trials of vaccines in healthy infants and young children will be conducted. Fully anonymised data from âˆ¼170 randomised controlled trials of v accines for diphtheria, tetanus, Bordetella pertussis, polio, Haemophilus influenzae type B, hepatitis B, Streptococcus pneumoniae, Neisseria meningitidis, measles, mumps, rubella, varicella and rotavirus will be combined for analysis. Outcomes include measures of immunogenicity (immunoglobulins), reactogenicity, safety and disease -specific clinical efficacy. Data from trials of vaccines containing similar components will be combined in hierarchical models and the effect of sex and timing of vaccinations estimated for each outcome separately. Systematic reviews of published estimates of sex-differences cannot adequately answer questions in this field since such comparisons are never the main purpose of a clinical trial, thus a large degree of reporting bias exists in the published literature. Recent improvements in the widespread availability of individual participant data from randomised controlled trials makes it feasible to conduct extensive individual participant data meta-analyses which were previously impossible, thereby reducing the effect of publication or reporting bias on the understanding of the infant immune response. Preliminary results will be available in 2016 with final results available in 2019. No ethics review is required for secondary analyses of anonymised data.
27473951	54	65	vaccination	T058	UMLS:C0042196
27473951	69	83	immunogenicity	T038	UMLS:C4277607
27473951	85	99	reactogenicity	T033	UMLS:C1691781
27473951	144	158	study protocol	T170	UMLS:C2348563
27473951	166	176	individual	T098	UMLS:C0237401
27473951	177	188	participant	T098	UMLS:C0679646
27473951	194	207	meta-analysis	T062	UMLS:C0920317
27473951	211	239	randomised controlled trials	T062	UMLS:C0206035
27473951	240	247	Disease	T038	UMLS:C0012634
27473951	301	311	infectious	T038	UMLS:C0009450
27473951	315	336	inflammatory diseases	T038	UMLS:C1290884
27473951	357	373	immune responses	T038	UMLS:C0301872
27473951	382	390	vaccines	T103	UMLS:C0042210
27473951	426	440	viral vaccines	T103	UMLS:C0042742
27473951	517	525	response	T033	UMLS:C1704632
27473951	529	541	immunisation	T058	UMLS:C0020971
27473951	601	609	vaccines	T103	UMLS:C0042210
27473951	670	686	coadministration	T058	UMLS:C1533734
27473951	696	704	vaccines	T103	UMLS:C0042210
27473951	729	744	immune response	T038	UMLS:C0301872
27473951	748	759	vaccination	T058	UMLS:C0042196
27473951	761	771	Individual	T098	UMLS:C0237401
27473951	772	783	participant	T098	UMLS:C0679646
27473951	789	802	meta-analysis	T062	UMLS:C0920317
27473951	806	834	randomised controlled trials	T062	UMLS:C0206035
27473951	838	846	vaccines	T103	UMLS:C0042210
27473951	936	964	randomised controlled trials	T062	UMLS:C0206035
27473951	970	977	accines	T103	UMLS:C0042210
27473951	982	992	diphtheria	T038	UMLS:C0012546
27473951	994	1001	tetanus	T038	UMLS:C0039614
27473951	1003	1023	Bordetella pertussis	T007	UMLS:C0006017
27473951	1025	1030	polio	T038	UMLS:C0032371
27473951	1032	1061	Haemophilus influenzae type B	T007	UMLS:C0121772
27473951	1063	1074	hepatitis B	T038	UMLS:C0019163
27473951	1076	1100	Streptococcus pneumoniae	T007	UMLS:C0038410
27473951	1102	1124	Neisseria meningitidis	T007	UMLS:C0027575
27473951	1126	1133	measles	T038	UMLS:C0025007
27473951	1135	1140	mumps	T038	UMLS:C0026780
27473951	1142	1149	rubella	T038	UMLS:C0035920
27473951	1151	1160	varicella	T038	UMLS:C0008049
27473951	1165	1174	rotavirus	T005	UMLS:C0035870
27473951	1196	1204	analysis	T062	UMLS:C0936012
27473951	1235	1249	immunogenicity	T038	UMLS:C4277607
27473951	1251	1266	immunoglobulins	T103	UMLS:C0021027
27473951	1269	1283	reactogenicity	T033	UMLS:C1691781
27473951	1296	1303	disease	T038	UMLS:C0012634
27473951	1343	1349	trials	T062	UMLS:C0008976
27473951	1353	1361	vaccines	T103	UMLS:C0042210
27473951	1425	1431	models	T170	UMLS:C3161035
27473951	1468	1480	vaccinations	T058	UMLS:C0042196
27473951	1520	1538	Systematic reviews	T170	UMLS:C1955832
27473951	1685	1699	clinical trial	T062	UMLS:C0008976
27473951	1724	1733	reporting	T058	UMLS:C0700287
27473951	1763	1773	literature	T170	UMLS:C0023866
27473951	1802	1812	widespread	T082	UMLS:C0205391
27473951	1829	1839	individual	T098	UMLS:C0237401
27473951	1840	1851	participant	T098	UMLS:C0679646
27473951	1862	1890	randomised controlled trials	T062	UMLS:C0206035
27473951	1930	1940	individual	T098	UMLS:C0237401
27473951	1941	1952	participant	T098	UMLS:C0679646
27473951	1958	1971	meta-analyses	T062	UMLS:C0920317
27473951	1994	2004	impossible	T033	UMLS:C0243095
27473951	2037	2048	publication	T170	UMLS:C0034036
27473951	2052	2061	reporting	T058	UMLS:C0700287
27473951	2074	2087	understanding	T038	UMLS:C0162340
27473951	2102	2117	immune response	T038	UMLS:C0301872
27473951	2213	2219	review	T170	UMLS:C0282443